Examples of what manufacturers must report to the MHRA under the medical device vigilance system when incidents involving their devices occur in the UK.
Similar Posts
Concizumab approved to prevent or reduce the frequency of bleeding episodes in people aged 12 years and older with haemophilia A or B with inhibitors
As with any medicine, the MHRA will keep the safety and effectiveness of concizumab under close review.
Consultation on Medical Devices Regulations: Routes to market and in vitro diagnostic devices
The MHRA is inviting members of the public to provide their views on proposed changes to the regulatory framework for medical devices.
Guidance: International Recognition Procedure
How to use the procedure for medicines licensing applications.
AI tools that could detect diseases earlier selected for next phase of MHRA’s ‘AI Airlock’ programme
Seven emerging AI healthcare technologies have been selected for the second phase of the MHRA’s AI Airlock programme.
Field Safety Notices: 28 July to 1 August 2025
List of Field Safety Notices from 28 July to 1 August 2025.
Transparency data: Medicines and Healthcare products Regulatory Agency Privacy Notice
This privacy notice describes how we collect and use your personal information, in accordance with the Data Protection Act and the General Data Protection Regulation.